Timothy Bouré and his co-founder Geoffrey Lucks were both near broke when they moved to Dallas to join the first accelerator they entered after forming VenoStent, a company that aims to improve outcomes for dialysis patients. Failed dialysis surgeries occur in roughly 55% to 65% of patients with end-stage renal disease, according to the company. […] …Continue Reading